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A B S T R A C T   
Purpose: Patients with end-stage kidney disease have an increased fracture risk. Whether mild to moderate re-
ductions in kidney function is associated with increased fracture risk is uncertain. Results from previous studies 
may be confounded by muscle mass because of the use of creatinine-based estimates of the glomerular filtration 
rate (eGFRcre). We tested the hypothesis that lower eGFR within the normal range of kidney function based on 
serum cystatin C (eGFRcys) or both cystatin C and creatinine (eGFRcrecys) predict fractures better than eGFR 
based on creatinine (eGFRcre). 
Methods: In the Tromsø Study 1994–95, a cohort of 3016 women and 2836 men aged 50–84 years had eGFRcre, 
eGFRcys and eGFRcrecys estimated using the Chronic Kidney Disease Epidemiology Collaboration equations. 
Hazard ratios (HRs) (95% confidence intervals) for fracture were calculated in Cox’s proportional hazards 
models and adjusted for age, height, body mass index, bone mineral density, diastolic blood pressure, smoking, 
physical activity, previous fracture, diabetes and cardiovascular disease. 
Results: During a median of 14.6 years follow-up, 232, 135 and 394 women and 118, 35 and 65 men suffered 
incident hip, proximal humerus and wrist fractures. In women, lower eGFRcre did not predict fracture, but the 
risk for hip and proximal humerus fracture increased per standard deviation (SD) lower eGFRcys (HRs 1.36 
(1.16–1.60) and 1.33 (1.08–1.63)) and per SD lower eGFRcrecys (HRs 1.25 (1.08–1.45) and 1.30 (1.07–1.57)). In 
men, none of the eGFR estimates were related to increased fracture risk. In contrast, eGFRcys and eGFRcrecys 
were inversely associated with hip fracture risk (HRs 0.85 (0.73–0.99) and 0.82 (0.68–0.98)). 
Conclusions: In women, each SD lower eGFRcys and eGFRcrecys increased the risk of hip and proximal humerus 
fracture by 25–36%, whereas eGFRcre did not. In men, none of the estimates of eGFR were related to increased 
fracture risk, and each SD lower eGFRcys and eGFRcrecys decreased the risk of hip fracture by 15–18%. The 
findings particularly apply to a cohort of generally healthy individuals with a normal kidney function. In future 
studies, the association of measured GFR using the gold standard method of iohexol clearance with fractures risk 
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should be examined for causal inference. More clinical research is needed before robust clinical inferences can be 
made.   
1. Introduction 
Chronic kidney disease (CKD) affects approximately 10% of the adult 
population, and the incidence increases with advancing age [1]. In pa-
tients with CKD, fractures are associated with high morbidity, mortality 
and increased economic burden [2–5]. Patients with end-stage kidney 
disease have a higher fracture risk than the general population [6], but 
the risk for fractures in a general population with mild to moderate 
kidney function is unclear. 
The relationship between kidney function and bone mineral density 
(BMD) is not well-defined. Reduced kidney function was not associated 
with lower femoral neck BMD in one study [7], and only in men in 
another study, which was partly explained by circulating parathyroid 
hormone (PTH) levels [8]. Others have reported reduced kidney func-
tion to be associated with low BMD of the total hip, but not of the spine 
[9]. 
Accurate assessment of kidney function requires cumbersome and 
costly measurement of glomerular filtration rate (GFR) using exogenous 
filtration markers, such as iohexol clearance [10]. Due to the lack of 
feasibility of these methods in clinical practice and large epidemiolog-
ical studies, various equations have been developed to calculate vali-
dated estimates of GFR, based on endogenous biomarkers that are 
eliminated mainly by filtration through the glomeruli. In 2009, the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) pub-
lished an equation for eGFR based on serum creatinine (eGFRcre) and in 
2012 an equation based on cystatin C (eGFRcys) and both (eGFRcrecys) 
[11,12]. Both eGFRcre and eGFRcys are influenced by non-GFR related 
factors that may confound the association between GFR and outcomes 
[13,14]. Importantly, eGFRcre is influenced by muscle mass, which may 
confound the association with fractures. A patient with large muscle 
mass for age and sex may have false low eGFRcre and low fracture risk. 
Conversely, a patient with sarcopenia may have false high eGFR and 
high fracture risk. Cystatin C is almost independent of age, sex and 
muscle mass, but may be influenced by other factors such as diabetes, 
smoking, obesity and inflammation [15]. In internal validation of 
models, equations that incorporated both creatinine and cystatin C 
showed a better ability to detect true GFR than equations based on each 
marker alone [13]. Moreover, the eGFRcrecys equation is less biased by 
non-GFR related factors [14,16]. 
Studies of community-dwelling older adults that have measured 
both eGFRcre and eGFRcys have reported that eGFRcys or eGFRcr-
ecys, and not eGFRcre was associated with fracture risk, especially hip 
fracture risk [17–20]. However, the relationship between eGFRcre 
and fracture risk, may have been confounded by muscle mass, an 
important risk factor for fractures. Few population-based prospective 
studies have investigated the effect of kidney function on risk of 
fractures other than hip fractures [6,21]. In a systematic review and 
meta-analysis of the association between CKD, falls and fractures, 
most of the studies included elderly patients, with a median age over 
65 years [6]. We expand upon this literature by focusing on a younger 
population, the vast majority of whom have normal kidney function 
and by studying not only hip fracture but also proximal humerus and 
wrist fractures. 
The aims of this project were to investigate whether lower eGFR, 
calculated using creatinine, cystatin C and both (eGFRcre, eGFRcys, 
eGFRcre-cys), was associated with reduced BMD and increased fracture 
risk in women and men ≥50 years of age in the Tromsø Study. We tested 
the hypothesis that lower eGFRcys or eGFRcrecys within the normal 
range of kidney function is associated with reduced BMD and predict 
fractures better than eGFRcre in a general population with a high inci-
dence of fracture. 
2. Materials and methods 
The Tromsø Study is a single-center, population-based health study 
in Northern Norway, with seven surveys conducted in 1974, 1979–80, 
1986–87, 1994–95, 2001, 2007–08, and 2015–16 [22–25]. We used 
data from the fourth survey in 1994–95 (Tromsø 4) where all inhabitants 
in Tromsø over the age of 24 years were invited, and 27,158 subjects 
(72%) participated (Fig. 1). A total of 26,992 consented to medical 
research. After excluding 16,728 subjects below 50 years of age, 10,264 
subjects 50–94 years of age remained. After excluding 4398 subjects 
with missing measurements of creatinine or cystatin C, five subjects who 
moved before Tromsø 4 and nine subjects with pathological fracture, 
5852 subjects (3016 women and 2836 men) were left included in this 
cohort study. Of these, 123 subjects were missing valid BMD measure-
ments at an extended examination [22]. All participants gave their 
informed written consent. The study is approved by the Regional 
Committee for Medical and Health Research Ethics and the Norwegian 
Data Inspectorate and is conducted in accordance with the World 
Medical Association Declaration of Helsinki. 
At baseline, self-administered questionnaires were filled in. The 
participants reported whether they were currently smoking, a teetotaler 
and hours of moderate and hard physical activity during leisure time. A 
physical activity score was made by adding the hours/week of moderate 
and hard physical activity, giving the hours with hard activity double 
weight: score = moderate + 2 hard. Participants reported the use of 
blood pressure (BP) lowering drugs, oral corticosteroids and hormone 
replacement therapy (HRT), and whether they had diabetes, cardio-
vascular disease (CVD, angina, myocardial infarction and/or stroke), or 
a previous fracture of the hip and/or wrist. No participants reported to 
use bisphosphonates at baseline. 
At baseline, height and weight were measured in light clothing 
without shoes, and body mass index (BMI) was calculated as weight 
divided by the square of height (kg/m2). BMD was measured at the non- 
dominant distal forearm, with Single X-ray Absorptiometric (SXA)-de-
vices (DTX-100 Osteometer Medi Tech, Inc., Hawthorne, California) and 
the coefficient of variation (CV) was 0.8% [26]. BMD was not measured 
at the hip, and a total body scan for assessment of muscle mass was not 
performed. Detailed description of the measurement methods, the strict 
quality control procedures for densitometry and long-term performance 
of the densitometers are previously published [22,24,27]. The systolic 
and diastolic BP was measured 3 times and we used the mean values 
from the second and third measurements. Non fasting blood samples 
were drawn and analyzed at the Department of Clinical Chemistry, 
University Hospital of North Norway, Tromsø [28]. Plasma creatinine 
was originally analyzed by a modified Jaffe reaction [29,30]. The 
plasma and serum samples were further stored at − 70 ◦C. As the CKD- 
EPI equation used for estimation of eGFRcre is validated for enzymatic 
creatinine measurements, 111 plasma samples were thawed and rean-
alyzed with an enzymatic method (Modular P/Roche Diagnostics) in 
2006. This is an isotope dilution mass spectrometry (IDMS) traceable 
assay, i.e. a standardized method. The plasma samples were randomly 
selected from the range of creatinine between 40 and 180, and rean-
alyzed creatinine values were fitted to a linear regression model, 
whereupon adjusted plasma creatinine values were calculated for all 
participants [29]. Cystatin C was analyzed in 2007 and 2009 from frozen 
serum in a Modular E analyzer (Roche Diagnostics, Mannheim, Ger-
many) with turbidimetric immunoassay (Gentian AS, Moss, Norway), 
and intraassay CV was 4.0% [30]. The 52 samples with cystatin C values 
below the limit of detection (0.45 mg/L) were given a value midway 
between zero and the limit of detection (0.22 mg/L). Detailed de-
scriptions of measurements of lipids, PTH and high-sensitive C-reactive 
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protein (hs-CRP) have been published [31,32]. The plasma creatinine 
and serum cystatin C levels were used to estimate GFR, according to the 
CKD-EPI equations [12]. 
All non-vertebral fractures that occurred during follow-up were 
identified from the radiographic archives of The University Hospital of 
North Norway in Tromsø between their participation in the 1994–95 
survey and 1 January 2010 [33]. All non-vertebral fractures were 
registered here because this was the only provider of diagnostic radi-
ology for fractures in Tromsø or within 250 km. The only exception 
would be fractures occurring while traveling with no radiographic 
control after returning. However, few patients with vertebral fractures 
are diagnosed at the hospital with an x-ray, and therefore vertebral 
fractures were not included in the x-ray-based registry. Of all the frac-
tures, this study included osteoporotic fractures as fractures of the hip, 
proximal humerus and wrist. The validation of the fracture registration 
has been reported [34]. Follow-up time was assigned from the date of 
the baseline visit to the date of the first fracture, to death, when the 
participant moved or end of follow-up (1 January 2010), whichever 
occurred first. Analyses of fractures of the hip included the first hip 
fracture that happened during follow-up, with the same procedure for 
the first fractures of the proximal humerus and wrist fracture. 
The SAS Software package, v9.4 (SAS Institute Inc., Cary, NC, USA) 
was used for statistical analyses. The characteristics of the women and 
men are reported as mean and standard deviation (SD) for continuous 
variables and as number (n) and percentage (%) for categorical vari-
ables. The data from women and men were divided into quartiles ac-
cording to eGFRcre, eGFRcys and eGFRcrecys. The associations of each 
of the kidney function estimates with BMD and fracture risk were 
assessed using eGFR as a continuous variable and as quartiles. Linear 
regression analysis was used to assess the association between eGFR and 
BMD, analysis of variance (ANOVA) to compare the groups (with the 
upper quartile as the reference) and adjusted for covariates. Linear 
regression analysis was used to test p for linear trends across the quar-
tiles, by including the ordinal variable with 4 levels as an independent 
variable. 
Cox’s proportional hazards model was used to determine whether 
eGFR predicted fractures. To facilitate the comparison of the effect es-
timate of eGFRcre, eGFRcys and eGFRcrecys on fracture risk, we pre-
sented the hazard ratios (HRs) per SD difference in eGFR. Sensitivity 
analyses was performed for the fracture outcomes excluding participants 
with CKD defined as eGFR <60 ml/min/1.73 m2. In addition, the HRs 
were quantified by including the group variables (dummies) with the 
upper quartile as the reference group. Finally, we examined whether 
women and men with CKD defined as eGFRcre, eGFRcys or eGFRcrecys 
<60 ml/min/1.73 m2, had increased risk of fracture compared with 
those who had levels ≥60 ml/min/1.73 m2. The proportionality as-
sumptions of the models were verified by inspection of survival plots. 
Analyses were performed sex-stratified due to well-known differences in 
kidney function and fracture rates between women and men. Further-
more, interactions between sex and eGFRcre, eGFRcys and eGFRcrecys 
were tested in models of BMD and in models of hip fractures as end-
points. As age influence both eGFR and fracture risk we tested for 
interaction between age (< 65 vs. ≥65 years) and all the estimates of 
eGFR in models of hip fractures. The analysis were adjusted for age, 
height, BMI, distal forearm BMD, current smoking (yes/no), alcohol 
intake (teetotaler, yes/no), the use of HRT (yes/no), the use of oral 
corticosteroids (yes/no), physical activity score, a history of previous 
fracture (yes/no), diabetes (yes/no), and CVD (yes/no), the use of any 
BP lowering drugs (yes/no) and diastolic BP, the calciotropic hormone 
PTH and inflammatory marker hs-CRP in both sexes, all known to be 
associated with kidney function and fracture risk [35–38]. In the final 
models we kept included the significant covariates, which differed be-
tween sexes. The covariates were added one by one to explore the rea-
sons why some associations changed from non-significant to significant. 
PTH and hs-CRP were log-transformed due to skewed distribution and 
were included in the analysis to explore biological mechanisms. P-values 
<0.05 were considered as statistically significant. 
Fig. 1. Participants from the Tromsø 4 study in 1994–95.  
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3. Results 
At baseline, mean age (range) was 63.5 years (50–84) in women and 
62.8 years (50–84) in men (Table 1). Mean ± SD eGFRcre, eGFRcys and 
eGFRcrecys was 89.6 ± 11, 87.4 ± 18.4 and 89.5 ± 15.3 (ml/min/1.73 
m2) in women and 91.1 ± 12.0, 91.6 ± 20.2 and 92.8 ± 15.9 (ml/min/ 
1.73 m2) in men. The number and proportion of women with CKD 
defined as eGFRcre, eGFRcys and eGFRcrecys <60 ml/min/1.73 m2 
were 73 (2.4%), 216 (7.2%) and 99 (3.3%) and corresponding number 
and proportion of men were 65 (2.3%), 155 (5.5%) and 88 (3.1%). The 
number of women and men with missing values for some variables are 
shown (Table 1). 
In models of BMD, there was a marginal interaction between sex and 
eGFRcre (p = 0.074), but not between sex and eGFRcys (p = 0.598) or 
sex and eGFRcrecys (p = 0.729). In women, higher eGFRcre and 
eGFRcrecys were associated with lower BMD after adjustment for 
covariates (β = − 0.44, p < 0.001 and β = − 0.25, p = 0.002, Supple-
mentary Table 1). In adjusted models, women in the lowest vs. upper 
quartile of eGFRcre had a mean BMD of 393 vs. 382 mg/cm2, while 
those in the lowest vs. upper quartile of eGFRcrecys had a mean BMD of 
390 vs.383 mg/cm2 (Table 2). In men, higher eGFRcre was associated 
with lower BMD after adjustment for covariates (β = − 0.37, p = 0.001). 
In the adjusted model, men in the lowest vs. upper quartile of eGFRcre 
had a mean BMD of 540 vs. 529 mg/cm2 (Table 2). In both sexes, 
eGFRcys was not associated with BMD after adjustment for covariates. 
During a median of 14.6 years follow-up (range 0.02–15.3), and 
34,851 person-years, 232 (7.7%), 135 (4.5%) and 394 (13.1%) of 3016 
women suffered an incident hip, proximal humerus and wrist fracture, 
and the fracture rates were 6.1, 3.5 and 10.8 per 1000 person-years 
(Table 3 and Supplementary Tables 2–4). During 33,442 person-years, 
118 (4.2%), 35 (1.2%) and 65 (2.3%) of 2836 men suffered an inci-
dent hip, proximal humerus and wrist fracture, and the fracture rates 
were 3.5, 1.0 and 1.9 per 1000 person-years. 
In models of hip fractures, there was no interaction between sex and 
eGFRcre, but interactions between sex and eGFRcys (p < 0.001) and sex 
and eGFRcrecys (p = 0.003). In both sexes, lower eGFRcre was not 
associated with increased risk of any fracture type (Table 3). In women, 
the risk for hip and proximal humerus fracture increased per SD lower 
eGFRcys, HRs (95% confidence interval) were 1.36 (1.16–1.60) and 
1.33 (1.08–1.63), and lower eGFRcrecys HRs were 1.25 (1.08–1.45) and 
1.30 (1.07–1.57). In men, the risk of hip fracture decreased per SD lower 
eGFRcys and eGFRcrecys and changed from non-significant to signifi-
cant in multivariable models (HRs 0.85 (0.73–0.99) and 0.82 
(0.68–0.98)). No single covariate explained this change, which was 
explained by the combination of height, smoking and BMD. The change 
in association with eGFRcrecys was explained by height. Adjustment for 
PTH and hs-CRP did not change any of the results. In models of hip 
fractures, there was an interaction between age (<65 vs. ≥65 years) and 
eGFRcys in women (p = 0.049), but no other interaction between age 
and any estimates of eGFR in both sexes. Of 1652 women <65 years, 49 
had hip fractures, HR for hip fracture was 1.74 (1.25–2.41), and of 1364 
women ≥65 years, 183 had hip fractures and HR was 1.29 (1.07–1.54) 
in the full models. In sensitivity analysis, excluding participants with 
CKD according to eGFR value, hip fracture risk increased per SD lower 
eGFRcys (HR 1.25 (1.01–1.54)) in women and decreased per SD lower 
eGFRcre, eGFRcys and eGFRcrecys in men (HRs 0.73 (0.56–0.97), 0.82 
(0.69–0.96) and 0.74 (0.62–0.88)) (Table 4). 
The relationships of eGFR with fractures were linear in nature and 
there was no evidence of a threshold (Supplementary Tables 2–4). 
Women with eGFRcys in the lowest quartile had an increased risk of hip 
fracture compared with those in the upper quartile of eGFRcys (HR 2.09; 
95% CI 1.15–3.78) (Supplementary Table 3). Men with eGFRcys in the 
lowest quartile had a reduced risk of hip fracture compared with those in 
the upper quartile of eGFRcys (HR 0.57; 95% CI 0.33–0.99). Otherwise, 
there was no significant increased risk of any type of fracture across 
quartiles for eGFRcre, eGFRcys or eGFRcrecys in both sexes. 
Finally, women but not men with CKD defined as eGFRcys or 
eGFRcrecys <60 ml/min/1.73 m2 had increased risk for hip and prox-
imal humerus fracture. This was not the case when CKD was defined as 
eGFRcre <60 ml/min/1.73 m2 (Supplementary Table 5). The HRs for 
these types of fractures were ranging from 1.64 to 3.16 after adjustment 
for all the covariates in women with eGFRcys or eGFRcrecys <60 ml/ 
min/1.73 m2. 
Exclusion of 298 (9.9%) women using HRT and 146 individuals (82 
women and 64 men) with high-energy trauma involved due to e.g. 
traffic accidents, did not change the results. 
4. Discussion 
In this Norwegian population-based cohort, lower eGFR based on 
cystatin C as well as the combination of cystatin C and creatinine pre-
dicted fracture of the hip and proximal humerus, whereas eGFR based on 
Table 1 
Baseline characteristics of 3016 women and 2836 men in the Tromsø Study.   
Women Men 
Missing  Missing  






































eGFRcre from creatinine (ml/min/ 





eGFRcys from cystatin C (ml/min/ 





eGFRcrecys from creatinine and 



































History of diabetes, n (%)  14 105 
(3.5)  
11 98 (3.5) 












Oral corticosteroid use, n (%)  0 43 (1.4)  0 29 (1.0) 
Hormone replacement therapy use, 
n (%)  
0 298 
(9.9)   
Values are mean ± SD or n (%). Number of missing varied for some of the 
variables. 
eGFR = estimating glomerular filtration rate. 
a Hours of moderate activity + 2 times hours of hard activity. 
b History of angina, myocardial infarction and/or stroke. 
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creatinine did not predict fracture in women. In men none of the esti-
mates of eGFR were related to increased fracture risk. In contrast, 
eGFRcys and eGFRcrecys were inversely associated with hip fracture 
risk in men. As the number of participants with abnormal kidney func-
tion was small in this cohort, the findings particularly apply to a cohort 
of generally healthy individuals with a normal kidney function. At 
baseline, higher eGFRcre, but not eGFRcys was associated with a lower 
distal forearm BMD in both women and men, which is a new finding. 
In epidemiological studies, the relationship between kidney function 
and BMD is inconsistently reported and varies by skeletal site [8,39]. A 
population based study reported that decreased kidney function was 
related to lower femoral neck BMD in men, but not women [8]. This 
relationship was partly explained by higher PTH levels. Two studies 
reported no differences in hip BMD across quartiles of eGFRcys in 
women or men [19,20]. To our knowledge, no previous study has re-
ported such a paradoxical negative association between eGFRcre and 
distal forearm BMD as we did. This cohort, had predominately normal 
kidney function according to the eGFR, and only 2–7% of the partici-
pants had eGFR <60 ml/min/1.73 m2, which could explain the results. 
The intriguing findings that higher eGFRcre and not eGFRcys was 
associated with lower BMD, is almost certainly explained by con-
founding from muscle mass because it is likely that individuals with 
lower BMD have less muscle mass and falsely higher eGFRcre. This 
would further highlight why creatinine is not an optimal measure of 
kidney function. Moreover, bone quality may be compromised with 
reduced kidney function without low BMD [40]. 
Previous studies on the relationship between kidney function and 
fracture risk have had some limitations [6]. Different methods have been 
used for assessment of kidney function such as the four variable MDRD 
equation to calculate eGFR based on creatinine [17], the CKD-EPI 
equation to calculate eGFR based on creatinine [8] and based on cys-
tatin C [18]. A majority of the studies examined the association between 
eGFR and the risk of hip fracture only, and most studies used eGFR based 
on creatinine [6]. However, the studies that have used both creatinine 
and cystatin C to calculate eGFR according to the CKD-EPI equations, 
reported consistently that eGFRcys or eGFRcrecys, and not eGFRcre, was 
associated with hip fracture risk [6,19,20,41,42]. Other studies have 
included individuals with a mean age of 75–80 years where 25–33% had 
eGFRcys <60 ml/min/1.73 m2 [6,8,19,43], whereas the current study 
was population-based and included relatively healthy individuals with a 
lower mean age of about 63 years and only 5–7% with eGFRcys <60 ml/ 
min/1.73 m2. 
In the current study, the association between lower eGFRcys and risk 
of fracture was sex specific. In women, results were consistent and 
robust as eGFRcys predicted fracture before and after adjustment for 
BMD and other covariates, and also in analysis with CKD defined as 
eGFRcys <60 ml/min/1.73 m2. The increased risk of fractures in women 
with lower eGFRcys, confirms the findings reported by Ensrud et al., that 
older women with higher cystatin C, but not higher creatinine, had an 
increased risk of hip fracture independent of other risk factors [19]. In 
another study by Ensrud et el., postmenopausal women with mild kid-
ney dysfunction assessed with eGFRcys had increased risk of non-
vertebral fracture [18]. Ensrud et al. also reported that men with lower 
eGFRcys had a 1.6 fold increased risk of hip fracture, but this was 
explained largely by other traditional risk factors [20]. As in this study, 
they reported that lower eGFRcre and eGFRcrecys were not associated 
with a risk of hip fracture in men. Our results showed an apparent 
protective effect of decreased eGFRcys on the risk for hip fractures in 
men. As this finding was independent of BMI, PTH and CRP, it was less 
likely confounded by obesity, secondary hyperparathyroidism or 
inflammation. The associations were weak and must be interpreted 
cautiously, however, the associations were confirmed in the sensitivity 
analysis. 
There was no association detected between eGFRcre and fracture risk 
in both sexes. Creatinine is dependent on muscle mass, which is an 
important determinant of fracture risk. Frail individuals with lower 
muscle mass may therefore have a falsely high eGFRcre compared to 
individuals with higher muscle mass. In the current cohort, the cystatin 
C based eGFR yielded a higher proportion of eGFR <60 ml/min/1.73 m2 
than the creatinine-based eGFR. This might reflect the independence of 
cystatin C with muscle mass in older adults [44]. This could also explain 
why eGFR based on cystatin C was superior to eGFR based on creatinine 
in predicting fracture risk in women in this study of a population with 
normal range of kidney function. 
Although cystatin C based eGFR is less dependent on muscle mass it 
is generally not superior to creatinine in assessment of GFR [12,13]. 
Table 2 
Mean (95% CI) bone mineral density (BMD) of the distal forearm (mg/cm2) by quartiles of estimates of glomerular filtration rate (ml/min/1.73 m2) calculated based on 
creatinine (eGFRcre), cystatin C (eGFRcys) and both (eGFRcrecys) by sex. The Tromsø Study 1994–95.   
Women Men 
Mean BMD (95% CI)a Mean BMD (95% CI)b Mean BMD (95% CI)a Mean BMD (95% CI)c 
n = 2948 n = 2942 n = 2781 n = 2767 
eGFRcre (ml/min/1.73 m2) 
<84.8 396 (391–400) 393 (388–397) 544 (539–549) 540 (535–546) 
84.8–92.6 392 (388–397) 392 (387–396) 539 (534–544) 536 (531–541) 
92.7–98.3 383 (379–387) 384 (380–388) 527 (522–532) 529 (524–533) 
>98.3 379 (374–384) 382 (377–387) 525 (520–530) 529 (524–534) 
P for trend <0.001 <0.001 <0.001 <0.001  
eGFRcys (ml/min/1.73 m2) 
<78.1 389 (384–393) 386 (382–390) 531 (525–536) 530 (525–536) 
78.1–91.0 390 (386–394) 391 (387–395) 536 (531–541) 536 (531–540) 
91.1–102 386 (382–390) 387 (383–391) 531 (526–536) 530 (25–535) 
>102 386 (381–392) 387 (382–393) 535 (530–539) 536 (531–540) 
P for trend 0.320 0.925 0.570 0.378  
eGFRcrecys (ml/min/1.73 m2) 
<82.0 392 (388–396) 390 (386–394) 534 (529–540) 532 (527–537) 
82.0–92.4 390 (386–395) 390 (386–394) 537 (532–541) 536 (532–541) 
92.4–101 386 (382–391) 388 (384–392) 531 (526–536) 531 (526–535) 
>101 381 (376–386) 383 (377–387) 532 (527–536) 534 (530–538) 
P for trend <0.001 0.041 0.282 0.969  
a Adjusted for age using analyses of variance. 
b Adjusted for age, body mass index (BMI), height, smoking, physical activity, history of cardiovascular disease, use of hormone replacement therapy and corti-
costeroid in women. 
c Adjusted for age, BMI, height, diastolic blood pressure, smoking, physical activity, and use of any blood pressure lowering drugs in men. 
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Moreover, eGFRcys is reported to be associated with smoking, low 
physical activity, high triglycerides, high LDL cholesterol, low HDL 
cholesterol and obesity after adjustment for measured GFR (mGFR), 
using iohexol clearance, a gold standard for assessment of kidney 
function, suggesting that those associations could not be explained by 
kidney function alone [10]. Low-grade inflammation is reported asso-
ciated with fracture risk [45,46]. The prediction of fracture risk by 
eGFRcys in the present study is unlikely to be confounded by low-grade 
inflammation because this was independent of hs-CRP. However, bio-
markers for inflammation other than hs-CRP also correlate with cystatin 
C [14,19]. Although lower eGFRcys and eGFRcrecys increased the risk of 
hip and proximal humerus fracture in women independent of many 
covariates, residual confounding may exist. The associations of eGFR 
with fracture risk are multifactorial and complex. One reason why none 
of the eGFR estimates were associated with wrist fractures in both sexes 
in this cohort, might be that wrist fractures are common in younger and 
healthier individuals than hip and proximal humerus fractures that are 
common in older frail adults. 
This study adds to the growing evidence that eGFRcys predicts 
fractures in women [6]. Whether eGFRcre predicts fractures remains less 
clear, and suggests that fracture risk evaluation should rather use 
eGFRcys or eGFRcrecys as a marker of kidney function. For clinicians it 
is of relevance that eGFRcre, the most commonly used estimate of kid-
ney function in clinical routine was not related to risk of fracture in both 
sexes. At least for women, a measure of eGFRcys, even within the normal 
range, may be of benefit for assessment of fracture risk, while we do not 
know yet if this is the case for men. The question whether a causal as-
sociation exists between slightly reduced GFR and increased fracture 
risk, can only be answered by examining whether the gold standard for 
GFR measurement (iohexol clearance) predict fractures. Although 
measured GFR using iohexol clearance will not be feasible in clinical 
practice, its associations with fractures risk should be examined in both 
sexes in well-powered research studies to achieve a better understanding 
of the pathophysiology and causal inference. 
Table 4 
Sensitivity analysis of risk of hip, proximal humerus, or wrist fracture by eGFR based on creatinine, cystatin C and both in women and men after excluding participants 
with eGFR <60 ml/min/1.73 m2.  
Fracture site Women Men 
Fracture 
n 
HR (95% CI)a HR (95% CI)b Fracture 
n 
HR (95% CI)a HR (95% CI)c 
Per 1 SD lower eGFRcre  n = 2943 n = 2878  n = 2771 n = 2717 
Hip  223 1.03 (0.87–1.23) 1.04 (0.87–1.24)  115 0.71 (0.54–0.93) 0.73 (0.56–0.97) 
Proximal humerus  131 1.16 (0.93–1.43) 1.23 (1.00–1.53)  33 0.81 (0.50–1.33) 0.90 (0.56–1.44) 
Wrist  386 0.91 (0.79–1.04) 0.91 (0.80–1.05)  63 0.72 (0.49–1.04) 0.76 (0.52–1.10) 
Per 1 SD lower eGFRcys  n = 2800 n = 2738  n = 2681 n = 2629 
Hip  195 1.19 (0.97–1.46) 1.25 (1.01–1.54)  109 0.86 (0.73–1.02) 0.82 (0.69–0.96) 
Proximal humerus  117 1.15 (0.89–1.49) 1.19 (0.92–1.53)  31 0.96 (0.66–1.40) 0.91 (0.63–1.30) 
Wrist  368 0.96 (0.84–1.08) 0.98 (0.86–1.12)  62 1.25 (0.90–1.73) 1.25 (0.89–1.76) 
Per 1 SD lower eGFRcrecys  n = 2917 n = 2853  n = 2748 n = 2694 
Hip  212 1.12 (0.94–1.33) 1.16 (0.97–1.39)  112 0.77 (0.64–0.93) 0.74 (0.62–0.88) 
Proximal humerus  123 1.10 (0.87–1.37) 1.16 (0.92–1.45)  33 0.95 (0.63–1.41) 0.92 (0.62–1.37) 
Wrist  394 0.93 (0.83–1.04) 0.97 (0.85–1.10)  64 1.10 (0.91–1.50) 1.09 (0.80–1.49) 
SD unit for estimates of glomerular filtration rate based on creatinine (eGFRcre), cystatin C (eGFRcys) and both (eGFRcrecys) were 11.9, 19.4 and 15.7 ml/min/1.73 
m2, respectively. 
a Hazard ratio (HR) with 95% confidence interval (CI) adjusted for age using Cox’s proportional hazards model. 
b Adjusted for age, height, body mass index (BMI), bone mineral density (BMD), smoking, history of previous fracture and diabetes, high-sensitive C-reactive protein 
and use of corticosteroid and any blood pressure lowering drugs in women. 
c Adjusted for age, height, BMI, BMD, smoking, history of previous fracture, diabetes and cardiovascular disease, and use of any blood pressure lowering drugs in 
men. 
Table 3 
Risk of hip, proximal humerus, or wrist fracture by eGFR based on creatinine, cystatin C and both, by sex.  
Fracture site Women Men 
Fracture 
n 
HR (95% CI)a 
n = 3016 
HR (95% CI)b 
n = 2948 
Fracture 
n 
HR (95% CI)a 
n = 2836 
HR (95% CI)c 
n = 2779 
Per 1 SD lower eGFRcre 
Hip  232 1.06 (0.93–1.22) 1.06 (0.91–1.23)  118 0.81 (0.65–1.03) 0.85 (0.67–1.07) 
Proximal humerus  135 1.13 (0.95–1.35) 1.20 (1.00–1.45)  35 1.01 (0.69–1.47) 1.03 (0.72–1.48) 
Wrist  394 0.92 (0.82–1.03) 0.93 (0.83–1.05)  65 0.82 (0.60–1.13) 0.87 (0.63–1.19)  
Per 1 SD lower eGFRcys 
Hip  232 1.33 (1.14–1.55) 1.36 (1.16–1.60)  118 0.91 (0.77–1.07) 0.85 (0.73–0.99) 
Proximal humerus  135 1.31 (1.07–1.62) 1.33 (1.08–1.63)  35 1.13 (0.79–1.62) 0.99 (0.71–1.39) 
Wrist  394 0.96 (0.86–1.07) 1.00 (0.89–1.13)  65 1.16 (0.89–1.53) 1.12 (0.85–1.48)  
Per 1 SD lower eGFRcrecys 
Hip  232 1.22 (1.06–1.41) 1.25 (1.08–1.45)  118 0.86 (0.71–1.03) 0.82 (0.68–0.98) 
Proximal humerus  135 1.26 (1.04–1.52) 1.30 (1.07–1.57)  35 1.08 (0.75–1.55) 1.01 (0.71–1.45) 
Wrist  394 0.93 (0.83–1.04) 0.98 (0.87–1.10)  65 1.06 (0.81–1.39) 1.05 (0.79–1.38) 
SD unit for estimates of glomerular filtration rate based on creatinine (eGFRcre), cystatin C (eGFRcys) and both (eGFRcrecys) were 11.9, 19.4 and 15.7 ml/min/1.73 
m2, respectively. 
a Hazard ratio (HR) with 95% confidence interval (CI) adjusted for age using Cox’s proportional hazards model. 
b Adjusted for age, height, body mass index (BMI), bone mineral density (BMD), smoking, history of previous fracture and diabetes, high-sensitive C-reactive protein 
and use of corticosteroid and any blood pressure lowering drugs in women. 
c Adjusted for age, height, BMI, BMD, smoking, history of previous fracture, diabetes and cardiovascular disease, and use of any blood pressure lowering drugs in 
men. 
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The strengths of this study are its prospective design including a 
large sample of women and men from a general population with a high 
attendance rate and inclusion of incident fractures based on a validated 
fracture registry. Another strength is that we used both creatinine and 
cystatin C to calculate eGFR in a normal population. The sensitivity 
analysis confirming that lower eGFRcys was associated with increased 
risk of hip fracture in women and decreased risk of hip fracture in men, 
indicate that the results are valid for individuals with eGFRcys in the 
normal range and were not driven by a few participants with manifest 
CKD. Limitations of this study include low power (particular in men), 
residual confounding by unmeasured risk factors, such as falls, lean 
body mass, hip BMD and bone turnover markers, which could influence 
our findings. Moreover, as discussed above, all estimates of kidney 
function may be confounded, and analysis has not taken into account 
mortality as a competing risk. Our results should be interpreted 
cautiously. 
In conclusion, lower eGFR based on cystatin C was associated with 
increased risk of hip and proximal humerus fractures in women, whereas 
eGFR based on creatinine was not. In men, none of the eGFR estimates 
were related to increased fracture risk. However, lower eGFR based on 
cystatin C and the combination of cystatin C and creatinine were 
inversely associated with hip fracture risk. The findings particularly 
apply to relatively healthy individuals with a normal kidney function. 
We infer that fracture risk evaluation related to kidney function may be 
best assessed using eGFR based on cystatin C, or the combination of 
creatinine and cystatin C, as a marker of kidney function in clinical 
practice, at least in women. Further work is needed to assess whether 
this is the case in men, before robust clinical inferences can be made. 
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